Efficacy and safety of pegylated interferon-alpha 2a in patients with lamivudine-resistant HBeAg-positive chronic hepatitis B
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Suh, Dong Jin | - |
dc.contributor.author | Lee, Han Chu | - |
dc.contributor.author | Byun, Kwan Soo | - |
dc.contributor.author | Cho, Mong | - |
dc.contributor.author | Kweon, Young Oh | - |
dc.contributor.author | Tak, Won Young | - |
dc.contributor.author | Chon, Chae Yoon | - |
dc.contributor.author | Koh, Kwang Cheol | - |
dc.contributor.author | Lee, Young Sok | - |
dc.date.accessioned | 2021-09-06T11:31:36Z | - |
dc.date.available | 2021-09-06T11:31:36Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 1359-6535 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/106526 | - |
dc.description.abstract | Background: Lamivudine resistance develops in up to 80% of patients with chronic hepatitis B (CHB) after 5 years of treatment. Cross-resistance between nucleoside/ nucleotide analogues limits management options in these patients. To investigate the role of pegylated interferon-alpha 2a as rescue therapy in these patients, the efficacy and safety of pegylated interferon-alpha 2a between treatment-naive patients and lamivudine-resistant patients with hepatitis B e antigen (HBeAg)-positive CHB were compared. Methods: A total of 150 HBeAg-positive CHB patients were stratified according to prior treatment. Lamivudine-resistant patients (n=64) and treatment-naive patients (n=86) received pegylated interferon-alpha 2a once-weekly for 48 weeks and were followed-up for an additional 24 weeks. Primary end points were HBeAg loss and HBV DNA < 100,000 copies/ml at end of follow-up. Results: A total of 65 (76%) treatment-naive patients and 49 (77%) lamivudine-resistant patients completed treatment and 24 weeks of follow-up. Rates of HBeAg loss were comparable at end of follow-up between treatment- naive patients and lamivudine-resistant patients (20.9% and 23.4%, respectively; P=0.8423). Similarly, rates of HBV DNA< 100,000 copies/ml were comparable at end of follow-up between treatment-naive patients and lamivudine-resistant patients (20.9% and 21.9%, respectively; P=1.000). There was no statistically significant difference in alanine aminotransferase normalization rates between treatment-naive patients and lamivudine-resistant patients (36.0% and 29.7%, respectively; P= 0.4848). A total of one patient in each group achieved hepatitis B surface antigen (HBsAg) loss and seroconversion. The most common adverse events were those known to occur with pegylated interferon-alpha 2a therapy, and safety profiles were similar between both patient populations. Conclusions: Pegylated interferon-alpha 2a may be effective as a rescue therapy in patients with lamivudine-resistant HBeAg-positive CHB. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | INT MEDICAL PRESS LTD | - |
dc.subject | TERM-FOLLOW-UP | - |
dc.subject | PEGINTERFERON ALPHA-2A | - |
dc.subject | ADEFOVIR DIPIVOXIL | - |
dc.subject | ONGOING LAMIVUDINE | - |
dc.subject | YMDD VARIANTS | - |
dc.subject | HBSAG LOSS | - |
dc.subject | THERAPY | - |
dc.subject | VIRUS | - |
dc.subject | HBV | - |
dc.subject | SEROCONVERSION | - |
dc.title | Efficacy and safety of pegylated interferon-alpha 2a in patients with lamivudine-resistant HBeAg-positive chronic hepatitis B | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Byun, Kwan Soo | - |
dc.identifier.doi | 10.3851/IMP2664 | - |
dc.identifier.scopusid | 2-s2.0-84892378232 | - |
dc.identifier.wosid | 000329762400003 | - |
dc.identifier.bibliographicCitation | ANTIVIRAL THERAPY, v.18, no.6, pp.765 - 773 | - |
dc.relation.isPartOf | ANTIVIRAL THERAPY | - |
dc.citation.title | ANTIVIRAL THERAPY | - |
dc.citation.volume | 18 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 765 | - |
dc.citation.endPage | 773 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Virology | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Virology | - |
dc.subject.keywordPlus | TERM-FOLLOW-UP | - |
dc.subject.keywordPlus | PEGINTERFERON ALPHA-2A | - |
dc.subject.keywordPlus | ADEFOVIR DIPIVOXIL | - |
dc.subject.keywordPlus | ONGOING LAMIVUDINE | - |
dc.subject.keywordPlus | YMDD VARIANTS | - |
dc.subject.keywordPlus | HBSAG LOSS | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | VIRUS | - |
dc.subject.keywordPlus | HBV | - |
dc.subject.keywordPlus | SEROCONVERSION | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.